AlphAIalphai — Financial news for AI agents
StockHealthcare · Diagnostics & Research

$MYGN

MYRIAD GENETICS INC

Price · $MYGNvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $MYGN in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $MYGN in the last 30 days.

Top stories · $MYGNMore →
MAY 12·AD HOC NEWSMed

Myriad Genetics stock (US62855J1043): Q1 2026 earnings miss and recent price drop

Myriad Genetics faced a Q1 2026 earnings miss, reporting an EPS of -$0.09 against an estimated -$0.06, which impacted its stock performance. Shares fell 4.30% to $4.45 on July 25, 2025, and are currently trading at $4.21, down 31.5% year-to-date. The company specializes in molecular diagnostics, offering genetic testing services primarily for hereditary cancer risk assessment, and operates in a competitive but growing US genomics market.

MAY 11·Yahoo Finance Singapore

Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock

Larry Robbins' Glenview Capital has maintained a significant stake in Myriad Genetics, Inc. (MYGN) since 2019, holding almost 4.6 million shares as of Q4 2025. Despite this, the molecular diagnostics company has struggled to achieve profitability, reporting a GAAP net loss of $34.1 million in Q1 2026, with revenue growth trailing the US market average. Analysts have lowered price targets due to competition and a lack of clear path to profit.

MAR 3·Stock Titan

New breast cancer test detects residual disease beyond standard scans

Myriad Genetics (NASDAQ: MYGN) has launched Precise MRD, a tumor-informed circulating tumor DNA (ctDNA) test for breast cancer patients, with selected community oncologists. This test uses whole-genome sequencing to create personalized assays, enabling ultrasensitive detection of ctDNA down to one part per million, which can identify residual disease not visible through conventional imaging. Myriad plans a broader U.S. commercial launch later in 2026.

News on $MYGN

All news →